Waldron Private Wealth LLC Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Waldron Private Wealth LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,229 shares of the biopharmaceutical company’s stock after buying an additional 327 shares during the quarter. Waldron Private Wealth LLC’s holdings in Gilead Sciences were worth $945,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. Algert Global LLC acquired a new stake in Gilead Sciences during the second quarter worth about $254,000. Quarry LP purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $43,000. Cetera Investment Advisers increased its position in Gilead Sciences by 1.8% during the 2nd quarter. Cetera Investment Advisers now owns 217,702 shares of the biopharmaceutical company’s stock worth $14,937,000 after purchasing an additional 3,801 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Gilead Sciences in the second quarter valued at approximately $7,847,000. Finally, Centaurus Financial Inc. lifted its position in Gilead Sciences by 12.4% during the second quarter. Centaurus Financial Inc. now owns 4,798 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 529 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent research reports. Robert W. Baird increased their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Sanford C. Bernstein began coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Oppenheimer upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $97.20 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a 50-day simple moving average of $92.42 and a 200 day simple moving average of $85.77. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a market cap of $121.14 billion, a PE ratio of 1,080.00, a P/E/G ratio of 1.34 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 456,234 shares of company stock worth $42,130,461. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.